Revvity, Inc. Stock News

Revvity's (RVTY) first-quarter results showcase a decline in life sciences segmental revenues. However, the company's earnings and revenues beat their respective estimates.

While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare t

Revvity (RVTY) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.01 per share a year ago.

Revvity on Monday beat Wall Street estimates for its quarterly profit and revenue, helped by better-than-expected demand for equipment in its diagnostics unit.

Revvity's (RVTY) latest offering is likely to provide a new and improved workflow to lower hands-on time and enable increased lab productivity.

Revvity's (RVTY) latest offering is likely to significantly accelerate the pace of drug innovation, with efficient data sharing into one seamless platform.

Revvity (RVTY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in

Revvity's (RVTY) strong product portfolio raises optimism about the stock.

Revvity's (RVTY) latest next-generation suite is likely to enhance research productivity and innovation.

Revvity's (RVTY) next-generation newborn sequencing research workflow is likely to build the foundation for diagnosing rare diseases in the future.

Revvity's (RVTY) fourth-quarter results showcase the decline in segmental revenues. However, the company's earnings and revenues beat their respective estimates.

The headline numbers for Revvity (RVTY) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estim

Revvity, Inc. (RVTY) CEO Prahlad Singh presents at 42nd Annual J.P. Morgan Healthcare Conference (Transcript)

Revvity's (RVTY) EONIS Q System is set to transform SMA and SCID testing, advancing global healthcare for infants.

Revvity, Inc. (NYSE:RVTY ) Q3 2023 Earnings Conference Call October 30, 2023 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President Investor Relations Prahlad Singh - President and C